| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CNTFR |
| Uniprot No | P26992 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-346aa |
| 氨基酸序列 | QRHSPQEAPHVQYERLGSDVTLPCGTANWDAAVTWRVNGTDLAPDLLNGS QLVLHGLELGHSGLYACFHRDSWHLRHQVLLHVGLPPREPVLSCRSNTYP KGFYCSWHLPTPTYIPNTFNVTVLHGSKIMVCEKDPALKNRCHIRYMHLF STIKYKVSISVSNALGHNATAITFDEFTIVKPDPPENVVARPVPSNPRRL EVTWQTPSTWPDPESFPLKFFLRYRPLILDQWQHVELSDGTAHTITDAYA GKEYIIQVAAKDNEIGTWSDWSVAAHATPWTEEPRHLTTEAQAAETTTST TSSLAPPPTTKICDPGELGSGGGP |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CNTFR(睫状神经营养因子受体)重组蛋白的3篇示例文献摘要，供参考：
---
1. **文献名称**: "Crystal structure of the CNTF–CNTFRα–gp130–LIFR complex"
**作者**: Davis S. et al.
**摘要**: 解析了CNTF与CNTFRα、gp130、LIFR形成的复合物晶体结构，揭示了CNTFRα在受体激活中的关键作用，为重组蛋白设计提供结构基础。
2. **文献名称**: "Functional characterization of a recombinant human CNTFRα variant"
**作者**: Ip N.Y. et al.
**摘要**: 通过哺乳动物细胞表达系统成功制备重组人CNTFRα蛋白，验证其与CNTF结合活性及促进神经元存活的生物学功能，证实其潜在治疗价值。
3. **文献名称**: "CNTFRα regulates astrocyte differentiation via JAK-STAT signaling"
**作者**: Di Marco A. et al.
**摘要**: 利用重组CNTFRα蛋白研究其在星形胶质细胞分化中的作用，证明其通过激活JAK-STAT通路调控神经胶质细胞发育。
---
**备注**：以上文献信息为示例，实际引用需通过PubMed、Web of Science等平台核对作者、年份及原文内容。建议结合具体研究方向补充最新研究。
Ciliary neurotrophic factor receptor (CNTFR) is a cytokine receptor that plays a critical role in neuronal development, survival, and synaptic plasticity. It is part of the interleukin-6 (IL-6) receptor family and primarily binds to ciliary neurotrophic factor (CNTF), a neurotrophic cytokine. CNTFR consists of three subunits: a ligand-binding α subunit (CNTFRα), and two signal-transducing subunits, gp130 and leukemia inhibitory factor receptor β (LIFRβ). Unlike other cytokine receptors, CNTFRα is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage, enabling its release as a soluble receptor under specific conditions. This unique structure allows CNTFR to mediate both membrane-bound and soluble signaling pathways.
CNTFR signaling activates JAK-STAT, MAPK, and PI3K-Akt pathways, promoting neuronal survival, glial cell differentiation, and metabolic regulation. It is particularly vital in the nervous system, supporting motor neurons and retinal ganglion cells. Dysregulation of CNTFR pathways has been implicated in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, making it a therapeutic target.
Recombinant CNTFR proteins are engineered using expression systems like *E. coli* or mammalian cells to mimic natural CNTFRα or soluble receptor complexes. These proteins retain bioactivity and are used in research to study neuroprotection, neuroregeneration, and metabolic interactions. In therapeutic contexts, recombinant CNTFR has shown potential in preclinical models for treating nerve injuries and metabolic disorders. However, challenges remain in optimizing stability, delivery, and minimizing off-target effects. Overall, CNTFR recombinant proteins serve as valuable tools for understanding neurotrophic signaling and developing interventions for neurological and metabolic diseases.
×
